IMI_SOPHIA

Stratification of Obese Phenotypes to Optimize Future Obesity Therapy (SOPHIA) is a Public-Private Partnership with over 30 international partners ranging from healthcare professionals, academia, industry leaders, and patient organizations working together to optimise the future of obesity care. Using machine learning, federated health data, and a unique approach to shared value, the project aims to improve the risk assessment of complications of obesity and better predict treatment response. Project timeline: June 2020 - February 2026 Budget: € 16 Million Coordination: University College Dublin, Prof Carel le Roux Project Lead: Novo Nordisk A/S, Mette Thomsen This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875534. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, and Obesity Action Coalition through the Innovative Medicines Initiative (IHI). The Innovative Health Initiative (IHI), formerly the Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). https://www.ihi.europa.eu/ *Posts on this platform only reflect the views of the SOPHIA Consortium.